-
Dynavax: Buy On Weakness Ahead Of November's PDUFA Date
Wednesday, September 13, 2017 - 9:43am | 565Read More...Dynavax Technologies Corporation (NASDAQ: DVAX) is awaiting its tryst with the FDA after a failed attempt in August. Against this backdrop, analyst Cathy Reese of Empire Asset Management Company recommended buying the shares of the company ahead of the November PDUFA date. As such, the firm has a...
-
Sell Insulet, Empire Warns
Thursday, February 25, 2016 - 10:42am | 268Read More...Empire Asset Management issued a note on Insulet Corporation (NASDAQ: PODD) after recent analysis of the company's core business capabilities, specifically its insulin delivery pump "OmniPod." Analysts initiated coverage of Insulet with a Sell rating and a $15 price target....
